| Description | This product is a monoclonal antibody derived from Mouse (Mus musculus), which can specifically recognize CD22 molecule. The antibody is expressed with mammalian cell transient expression system, serum-free and purified by affinity chromatography. The purity and integrity are tested via SDS-PAGE and SEC-HPLC analysis. Given an antigen, additional QC measures are also desired such as affinity testing and binding validation. Specifically, the antibody is provided in multiple formats for in vivo and in vitro assays. The Invivo version features greater than 95% purity, ultra-low endotoxin levels (<1 EU/mg or 0.1 EU/mg), and is preservative, stabilizer, and carrier protein-free. |
| Clonality | Monoclonal |
| Host Species | Mouse |
| Target Species | Human |
| Immunogen | Human CD22 his-8 tagged extracellular domain lacking domains 3 and 4 |
| Epitope | Within the ECD domain. |
| Affinity | KD = 15 nM, determined by surface plasmon resonance. |
| Isotype | IgG |
| Expression Species | HEK293F or CHO |
| Conjugation | None |
| Purity | >95%, determined by SDS-PAGE and/or SEC-HPLC |
| Endotoxin | <1 EU/mg, determined by LAL method |
| Purification | Protein A affinity purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4⁰C within a week. For longer storage, aliquot and store at -20⁰C. |
| Application | ELISA; WB; FC; RIA |
| Application Notes | The antibody is recommended for detection of CD22 by ELISA, WB, FC, RIA assays. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | CD22 |
| Alternative Name | CD22 Molecule; CD22 Antigen; Sialic Acid Binding Ig-Like Lectin 2; Sialic Acid-Binding Ig-Like Lectin 2; B-Lymphocyte Cell Adhesion Molecule; T-Cell Surface Antigen Leu-14; SIGLEC-2; SIGLEC2; BL-CAM |
| Gene ID | 933 |
| UniProt | P20273 |
| Research Area | Immunology; Cancer Research |
| Related Disease | B cell-related disorders include, but are not limited to, malignant lymphoma, multiple myeloma, and chronic lymphocytic leukemia |
